The DEA (the US agency that controls which drugs are legal) won't change the status of MDMA or psilocybin until the FDA (the US drug regulator) officially approves one of them as a medicine — and that approval hasn't happened yet. Until it does, both substances remain in the strictest legal category, meaning possession and use are federal crimes. This affects millions of people who might benefit from these treatments but can't access them legally.
Federal rescheduling is statutorily tied to FDA approval, which has not occurred. Absent an approved product, DEA has no procedural trigger to reschedule, and enforcement posture is expected to hold. Consensus across DEA, legislator, and FDA reviewer agents; sole dissent from MAPS researcher reflects advocacy bias rather than a likely mechanism.